OverviewSuggest Edit
ImmuPharma is a pharmaceutical company focused on developing innovative drugs to treat serious medical conditions in specialist therapeutic areas. Its low risk-strategy is to work closely with the largest fundamental research institutions, which allows access to scientists and doctors, keeping costs low by avoiding the constant funding necessary for early-stage research. The Company offers Lupuzor, a treatment for Lupus and its most advanced drug candidate.
| Type | Public | |
| Founded | 1999 | |
| HQ | London, GB | Map |
| Website | immupharma.co.uk |
Recent NewsAll News
- Immupharma shares take off as firm signs US lupus deal
- The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus
- The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating
Key People/Management at ImmuPharma
Tim McCarthy
Non-Executive Chairman
Robert Zimmer
President, Chief Science Officer & Director
Dimitri F Dimitriou
Chief Executive Officer, Co-Founder & Director
Stéphane Méry
Non-Executive Director
Tim Franklin
Chief Operating Officer
Lisa Baderoon
Head of Investor Relations
ImmuPharma Office Locations
ImmuPharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
Terminal House, 52 Grosvenor Gardens, Belgravia
London, GB
1 Bartholomew Cl
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
ImmuPharma Financials and Metrics
ImmuPharma Revenue
ImmuPharma's revenue was reported to be £81.28 k in FY, 2018
| GBP | |
|---|---|
Revenue (FY, 2018) | 81.3k |
Net income (FY, 2018) | (7.2m) |
EBITDA (FY, 2018) | (7.9m) |
EBIT (FY, 2018) | (8.1m) |
Market capitalization (5-Mar-2021) | 23.0m |
Closing stock price (5-Mar-2021) | 0.1 |
Cash (31-Dec-2018) | 4.9m |
EV | 18.2m |
ImmuPharma's current market capitalization is £23 m.
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 25.4k | 63.2k | 57.1k | 22.1m | 32.5k | 16.8k | 184.8k | 76.4k | 164.8k | 150.5k | 81.3k | ||||
Revenue growth, % | (59%) | ||||||||||||||
Operating expense total | (1.5m) | 3.6m | 4.6m | 11.8m | 4.2m | (3.8m) | 3.6m | 4.6m | 6.8m | 7.4m | 8.2m | ||||
EBITDA | (2.0m) | (3.5m) | (4.5m) | 10.3m | (4.1m) | 3.9m | (4.1m) | (4.2m) | (3.3m) | (4.4m) | (6.5m) | (7.1m) | (7.9m) |
| GBP | FY, 2001 | FY, 2002 | FY, 2003 | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 1.0 | 1.0 | 1.0 | 978.2k | 1.0m | 2.7m | 2.9m | 12.5m | 22.5m | 15.6m | 12.2m | 8.9m | 5.4m | 5.4m | 833.4k | 1.9m | 2.7m | 4.9m |
Accounts Receivable | 3.2k | 22.2k | 2.8k | 13.2k | ||||||||||||||
Current Assets | 1.0 | 1.0 | 1.0 | 979.9k | 1.0m | 2.9m | 3.3m | 12.6m | 23.9m | 16.8m | 13.5m | 9.8m | 6.5m | 6.1m | 2.4m | 6.0m | 4.4m | 6.0m |
PP&E | 12.0k | 12.8k | 13.3k | 9.3k | 76.8k | 125.4k | 114.8k | 97.1k | 366.4k | 280.1k | 231.9k | 161.4k | 164.7k |
| GBP | FY, 2004 | FY, 2005 | FY, 2006 | FY, 2007 | FY, 2008 | FY, 2009 | FY, 2010 | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.4k | 15.1k | (2.5m) | (3.1m) | 4.7m | 8.1m | (2.0m) | (3.4m) | (3.8m) | (3.7m) | (2.9m) | (3.9m) | (5.3m) | (6.2m) | (7.2m) |
Cash From Operating Activities | 15.8k | 18.3k | 879.6k | 3.8m | (3.6m) | 12.0m | (6.8m) | (3.4m) | (3.3m) | (3.9m) | (2.5m) | (4.1m) | (6.5m) | (4.4m) | (4.7m) |
Cash From Financing Activities | 977.0k | 3.0m | (77.6k) | 12.0m | (143.5k) | 555.2k | 165.3k | 356.9k | 191.5k | 3.0m | (310.1k) | 7.4m | 5.4m | 9.1m | |
Net Change in Cash | 978.2k | 27.1k | 2.7m | 3.7m | 8.5m | 11.9m | (6.4m) | (3.2m) | (2.8m) | (3.7m) | 199.0k | (4.5m) | 896.3k | 945.9k | 2.3m |
| GBP | FY, 2001 |
|---|---|
Financial Leverage | 1 x |
ImmuPharma Cybersecurity Score
ImmuPharma Online and Social Media Presence
588 Twitter followers
ImmuPharma has 588 Twitter Followers. The number of followers has increased 1.4% month over month and increased 9.9% quarter over quarter
ImmuPharma's Trends
Twitter Engagement Stats for @ImmuPharma
81
Tweets
61
Following
588
Followers
4
Tweets last 30 days
5.8
Avg. likes per Tweet
100%
Tweets with engagement
ImmuPharma News and Updates
November 28, 2019
Immupharma shares take off as firm signs US lupus deal
Specialist drug developer Immupharma rose almost 300 per cent today on the back of an exclusive US licensing deal for [...]
The post Immupharma shares take off as firm signs US lupus deal appeared first on CityAM.
September 09, 2019
The Life Sciences Division Update Report on ImmuPharma plc Post AstraZeneca plc Announcement of Anifrolumab Successfully Navigating a Second Phase III Clinical Trial in Lupus
LONDON, Sept. 9, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces an update report on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on...
May 28, 2019
The Life Sciences Division Initiates Coverage on ImmuPharma Plc With a BUY/Corporate Rating
LONDON, May 28, 2019 /PRNewswire/ -- The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, today announces the initiation of research on ImmuPharma plc, a pharmaceutical development company listed on AIM of the London Stock Exchange focusing on ...
ImmuPharma Blogs
February 09, 2021
Lupuzor™ scheduled to commence international Phase 3 trial in Lupus patients in H2 2021
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a potentially life-threatening auto-immune disease. …
January 18, 2021
Appointment of Company Secretary
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is pleased to announce that Ewa Flynn, the Company’s Financial Controller, was appointed as Company Secretary on 15 January 2021. To download announcement click here
The post Appointmen…
December 03, 2020
ImmuPharma to present at Biotech Showcase™ Digital 2021
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that Dr Tim Franklin, ImmuPharma’s Chief Operating Officer, will be presenting at the prestigious Biotech Showcase™ Digital 2021. The event will be virtually held between 11 and 15 January 2021. As part of ImmuP…
November 26, 2020
Grant of Share Options & PDMR dealing
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company (“Ordinary Shares”) to Directors, employees and consultants representing 3.8% …
November 20, 2020
FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”), a po…
November 10, 2020
Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces further regulatory and operational progress for the new optimised international Phase 3 trial of Lupuzor™ in systemic lupus erythematosus (“SLE”) a potentially life-threatenin…
ImmuPharma Frequently Asked Questions
When was ImmuPharma founded?
ImmuPharma was founded in 1999.
Who are ImmuPharma key executives?
ImmuPharma's key executives are Tim McCarthy, Robert Zimmer and Dimitri F Dimitriou.
How many employees does ImmuPharma have?
ImmuPharma has 17 employees.
What is ImmuPharma revenue?
Latest ImmuPharma annual revenue is £81.3 k.
What is ImmuPharma revenue per employee?
Latest ImmuPharma revenue per employee is £4.8 k.
Who are ImmuPharma competitors?
Competitors of ImmuPharma include Bracco, ProTab Laboratories and Akrivis Technologies.
Where is ImmuPharma headquarters?
ImmuPharma headquarters is located at Terminal House, 52 Grosvenor Gardens, Belgravia, London.
Where are ImmuPharma offices?
ImmuPharma has offices in London, Mulhouse and Sarnen.
How many offices does ImmuPharma have?
ImmuPharma has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies